Thema: US74340E1038
PGNY, US74340E1038
money-88409_1920.jpg - Foto: THN
Progyny stock study finds treatment gaps persist despite benefits
Progyny stock is in focus after new research examined treatment access among patients with fertility benefits. The study points to barriers beyond coverage.
ad-hoc-news.de, heute 03:05 Uhr
PGNY, US74340E1038
Progyny presents menopause research and Barclays holds Progyny ...
Progyny's study will be presented October 22, 2026 at 5:15 p.m. PT in San Diego at the meeting. Barclays holds Progyny stock at USD 30.00.
ad-hoc-news.de, 16.10.26 00:21 Uhr
PGNY, US74340E1038
Wells Fargo starts coverage of Progyny stock with a USD ...
Second-quarter revenue reached USD 350.51 million, up 5.30 percent year over year. Progyny stock was USD 25.86 on Nasdaq after USD 25.23.
ad-hoc-news.de, 06.10.26 03:43 Uhr
PGNY, US74340E1038
Progyny stock reports 5.3 percent revenue growth in Q2
Progyny stock posted diluted EPS of USD 0.34 in Q2 2026, up from USD 0.19 a year earlier. Bank of America disclosed 598,815 shares on September 25, 2026.
ad-hoc-news.de, 25.09.26 10:26 Uhr
PGNY, US74340E1038
Progyny stock falls 1 percent as valuation stays elevated ...
Progyny stock closed at USD 26.86 on September 18, 2026, down 1 percent from the prior close. Market value stood at USD 2.06 billion.
ad-hoc-news.de, 22.09.26 09:58 Uhr
PGNY, US74340E1038
Progyny stock steadies after soft Q2 guidance and revenue ...
Progyny stock is holding in the mid-$20s as investors digest Q2 2026 revenue growth, weaker guidance and the company’s role in employer fertility benefits.
ad-hoc-news.de, 29.08.26 17:28 Uhr
